A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms REFLEX
  • Sponsors Merck KGaA
  • Most Recent Events

    • 28 Oct 2017 Results of post hoc analysis of REFLEX and REFLEXION trials assessing the impact of gadolinium-enhancing (Gd+) lesions at baseline on NEDA presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 27 Jun 2017 Results (n=917) assessing predictive value of modified Rio score using patient data from REFLEX(ION), REGARD, SPECTRIMS and PRISMS trials presented at the 3rd Congress of the European Academy of Neurology
    • 28 Apr 2017 Results of post-hoc analysis conducted in the intent-to-treat population of this and REFLEXION trial presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top